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ABSTRACT v	  
Abstract 
The main objective of this thesis was to investigate skin reactions 
around percutaneous abutments in the facial and retroauricular re-
gions. Secondary objectives were to investigate the number of lost 
extraoral implants and their co-morbidity over time, for example 
complications because of skin reactions due to the skin penetrating 
abutment. Another aim was to develop a new surgical technique to 
improve and facilitate soft tissue healing, explore an alternative mate-
rial for the abutment to create a tighter adherence between dermis and 
the abutment surface and study the skin-abutment interface. 
To assess skin reactions and long-term outcome for extraoral im-
plants, a retrospective study on patients treated at the Sahlgrenska 
University hospital was performed and implant survival rate was es-
timated. This showed that a small group of 19 patients counted for 78 
(55 %) out of 141 (of total 763) of the lost implants. The over all im-
plant loss was 18 %. 
A new animal model (sheep) was designed to study different types 
of abutments. Cylindrical and concave shaped abutments with hy-
droxyapatite surface material were compared with conventional cy-
lindrical and concave titanium abutments. Samples were taken for 
histology, histomorphometric and qualitative analyses were carried 
out, showing integration between hydroxyapatite and dermis. The 
results suggested an advantage in using hydroxyapatite as abutment 
surface material. However the significance of the shape could not be 
determined. 
Thereafter, a second study was performed to compare and further 
investigate the effect of abutment shape during a healing period of 4 
weeks. Together, the animal studies 1 and 2 resulted in a new surgical 
procedure and feature of the abutment design. In sheep, the hydroxy-
apatite showed a firm integration with dermis. 
From previous knowledge about complications with percutaneous 
abutments and the findings from the animal model, a cylindrical hy-
droxyapatite covered healing abutment was designed for human use.  
This newly designed test abutment was used in a pilot study exam-
ining dermis-abutment interface after implant insertion up until the 
second stage surgery at 12 weeks healing. Samples were taken for 
 ABSTRACT VI 
histology and histomorphometric and qualitative analyses. Results 
from the first patients showed that the hydroxyapatite surface induces 
a different interphase with the dermis compared to the titanium sur-
face. 
Keywords; Hydroxyapatit, bone anchored hearing aid, percutane-
ous, abutment, and dermal integration.
 POPULÄRVETENSKAPLIG SAMMANFATTNING VII 
Hudgenomförande implantat - 
prognos och design 
Populärvetenskaplig sammanfattning 
Bakgrund: Det finns idag unika möjligheter att förankra titankomponenter i skelettet. I vissa 
fall är konstruktionen sådan att den behöver passera genom huden för att utgöra en förankrings-
punkt. Patienten kan sedan använda denna del för att koppla på en hörapparat eller en protes. 
Det finns dock komplikationer med benförankrade lösningar såsom; förlust av implantat och 
hudreaktioner av olika svårighetsgrader. Syftet med denna avhandling var att studera implantat-
överlevnaden och fördelningen av implantatförluster per patient, samt att studera ett alternativt 
material för hudgenomföring och en alternativ kirurgisk teknik.  
Delarbete I: Detta är en retrospektiv studie på 571 patienter (763 implantat) som behandlats 
med benförankrad hörapparat (BAHA) på Sahlgrenska Universitetssjukhuset 1977-2011. Stu-
dien visade att det totalt förlorades 141(18 %) implantat under en uppföljningstid 0-32 år (me-
del 6.6 år). Totalt 46 patienter (8.2 %) hade någon form av implantatförlust. Anmärkningsvärt 
var att 78 (55 %) av implantaten förlorades i en liten grupp på 19 patienter som alla förlorade 
två eller fler implantat. 
Delarbete II: En djurmodell utvecklades för att studera histologiskt om det med en hudgenom-
förande del i hydroxyapatite istället för titan samt för att studera om det utan hudtunning och ur 
ett interaktionsperspektiv mellan hud och distans, fungerar att använda hydroxyapatit på den 
hudgenomförande distansytan istället för titan vid BAHA implantat. Totalt placerades 36 im-
plantat i 6 st får i 1-4 veckor.  Studien visade att hydroxyapatite fungerar att användas utan 
hudtunning och utan avvikande fynd i jämförelse med titan.  
Delarbete III: Samma djurmodell användes för att studera hydroxyapatiten histologiskt i kon-
takt med hud. Totalt placerades 48 implantat i 8st får i 4 veckor. Studien visade att hydroxyapa-
tit på distansytan interagerar med hud på ett annat sätt än titan.  
Delarbete IV: En pilotstudie av hydroxyapatit i människa. Fyra patienter fick en hydroxyapa-
titdistans och en titandistans under 12 veckor i samband med annan planerad behandling för 
benförankrade proteser i ansiktsregionen. Studien visade att hydroxyapatitytan interagerar med 
hud på ett annat sätt än titan. Inga negativa kliniska effekter för patienterna noterades under 
studietiden. 
Slutsater: Rehabilitering med benförankrade hörapparater är en välfungerande behandling när 
indikation finns men en liten grupp patienter har problem med upprepade implantatförluster.  
Hydroxyapatit istället för titan på den hudgenomförnde distansytan i en djurmodell leder till 
tätare kontakt med hud och mjukvävnad. Det finns skäl att vidare studera och utveckla hyd-
roxyapatiten som hudgenomförande material i patienter. 
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1 Introduction 
1.1 Rehabilitation with skin penetrating implants 
Osseointegration was initially reported by Brånemark following observa-
tions in the 1950th during a study of bone marrow circulation in rabbit, as 
an en passant discovery. He noticed that bone overgrew the titanium 
chambers and in 1969 Brånemark et al. established the term osseointegra-
tion.(1) This pioneer research did not only define osseointegration, it also 
stated factors affecting osseointegration, materials, bone composition, 
necessary healing time and surgical technique. The foundation for re-
search exploring the unifying structure of bone tissue and titanium was 
laid.  
 The current field of osseointegration research mostly focus on the 
dynamics and the biomechanics of titanium implants for different appli-
cations. The bone integrated implant with abutment is widely used in 
medicine, an anchor for prostheses, epitheses or other devices, i.e. most 
frequently bone anchored hearing aids (BAHA). A lot of the experiences 
of osseointegration are established through intraoral implants and their 
longevity and pattern of complications.(2) Despite differences of the sur-
rounding tissue, biomechanics and dynamics of soft tissue passage and 
the bone seem to share some general principles. Reports suggest that the 
material and shape of implants and/or abutments, constitutions of surface 
and stability affect the dynamics and biomechanics.(3, 4) 
 However soft tissue interaction is of great importance as it is rele-
vant to the longterm prognosis of osseointegration for both percutaneous 
and mucosal abutments.(5-8) KM Holgers et al. 1987 considered that ad-
verse skin reactions could be a reason for implant failure. Furthermore, 
histological evaluations of lost percutaneous implants have been per-
formed showing patterns similar to lost retrieved intraoral implants.(4, 9-11) 
 The largest number of percutaneous abutments is the BAHA. Sens-
es are important to all living organisms. Hearing is one of our five senses 
(vision, smell, taste, hearing and touch). In the world, 5 % (360 million) 
of humans experience deafness or hearing loss reported by the World 
Health Organisation (WHO). Some reasons for impaired hearing are ge-
netics, birth complications, complications to infections, certain drugs, 
noise damage or aging. According to WHO more than 90 % of the people 
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with disabling hearing loss worldwide lack hearing aid 
(https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-
loss). 
 Patients who have lost a limb or other body parts due to trauma or 
severe illness can indeed benefit from a fixed prostheses or epitheses. In 
2005 it was estimated in the Unites states of America that 1.6 million 
people lived with some limbloss.(12) The conventional rehabilitation using 
a traditional prostheses, for example a leg, often implies socket problems 
and difficulties in usage and affects quality of life.(13) Hence, a method to 
adapt the prostheses directly to the skeleton would increase the patient 
benefit of treatment. This scheme of rehabilitation has been carried out 
since the 1990s by the Brånemark group in Sweden with success rates 
comparable to other percutaneous implants.(14) 
 It is a treatment associated with known complications.(14-16) The 
prognosis for percutaneous implants seems to depend on the dynamic 
unit of bone-implant and skin-abutment interfaces.(10, 17) 
1.1.1 Osseointegration 
The definition of osseointegration is based on four different viewpoints 
(P-I, Brånemark, The osseointegration book: From calvarium to calca-
neus, 2005, Quintessences Berlin Chicago). Firstly, micro-, and macrobi-
ological medical properties are defined as a functional unit of the implant 
without interposed scar tissue layer nor scar tissue, ligament or cartilage 
in between implant and bone. 
 Secondly, healthy bone tissue can be seen within the zone adjacent 
to the implant in light microscope and electron microscope.(18, 19) 
 Thirdly, no motion should be detected between the implant and the 
surrounding living bone and marrow at functional loading forces. Fur-
thermore this stability should remain longterm, preferably the patients 
entire life. The implant should respond to loading forces the same way as 
if load was directly on the bone.(1) 
 Last but not least, the clinical usage, providing a stable and immo-
bile support under functional loading forces, without pain, inflammation 
or loosening. Osseointegration is a dynamic process and the unifying of 
bone cells and titanium dioxide (TiO2) is a continuous process that can be 
disturbed by overload or inflammation process.  
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1.1.2 Bone Anchored Hearing Aid 
 Sound waves can reach the hearing organ (cochlea) through air 
conduction or bone conduction. When the cochlea is stimulated by air 
conduction, sound enters the ear canal and sets the tympanic membrane 
and the middle ear ossicles in motion, which in turn creates a wave mo-
tion of the cochlear fluids that stimulates nerve cell impulses that are 
transmitted to the brain stem and the auditory cortex of the brain. Hearing 
by bone conduction implies vibration stimulation of the skull bone where 
the vibrations reach and shake the cochlea which is stimulated in the 
same way as for air conduction.  
 Hearing loss due to a cochlear malfunction is commonly rehabili-
tated using conventional hearing aids that amplify incoming air conduct-
ed sound. With malformations of the ear canal, chronic discharging ears 
or hearing loss due to middle ear disease, hearing rehabilitation through 
bone conduction is preferred since this auditory route bypasses the ear 
canal and the middle ear.(20)  
  After Prof. Brånemark had defined osseointegration as the successful 
adaptation of titanium to bone tissue, new possibilities arose. It opened 
for the possibility to anchor external materials to skeletal structures. One 
innovation using osseointegration was the BAHA, Fig1.(21, 22) The BAHA 
uses the bone conducted hearing pathway. The audio processor is at-
tached to a percutaneous titanium implant, which is osseointegrated in 
the parietal bone of the skull. Sound is converted from sound waves in 
the air to mechanical vibrations of the skull bone, and is transmitted to 
the cochlea.(20-23) Since 1977, the BAHA has spread all over the world.   
 
 
 
 
 
Figure 1 BAHA sound processor (left), BAHA abutment (right) 
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The BAHA treatment is from a surgical and osseointegration aspect ra-
ther standardised but there are complications. As the osseointegrated im-
plant remains in the bone, the percutaneous abutment at times causes a 
variety of skin complications.(15, 24, 25) 
1.1.3 Percutaneous osseointegrated craniofacial prosthe-
ses 
Osseointgrated implants are also used in the head and neck region for 
rehabilitation of craniofacial defects, Fig 2.(22, 26-28)  
 Implant retained prostheses contribute to an increased stability, safety 
and satisfaction, compared to traditional adhesive solutions.(29) Success 
rates for non-irradiated patients are 95 % and in irradiated patients 80 
%.(27)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Ear prosthese/epithesis (left), abutment bar construction attachment with skin reaction (right)  
1.1.4 Percutaneous osseointegrated prostheses for trans-
femoral amputations 
Another application is the possibility to anchor limb prostheses directly 
to the skeleton via osseointegration. More than 200 patients have been 
treated this way in Sweden.(14, 30) The rehablitiation gives the patients an 
increased ability of movement and tactile perception.(31, 32) 
 But as with other percutaneous solutions the treatment is jeopardised 
by complications such as skin infections. Soft tissue infections and other 
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problems are reported to be up to 47 %.(33) Studies of different abutment 
designs have been published without showing improvement of skin con-
ditions. Infact some cases with a rough titanium surface show even high-
er frequencies of infection, due to a more readily formation of biofilm. 
Shin et al. 1997 found that glassy carbon and pouros HA did not affect 
the soft tissue.(25) However, studies with sheep and porous titanium 
showed favourable results for the soft tissue outcome.(34, 35) Also animal 
trials with flange design to improve the percutaneous passage have been 
successful.(36)  
1.2 Skin 
Our largest organ is our envelope - skin (integument). It will shield us 
from the external environment but also function as a tactile organ. Skin 
together with mucosa is continuous with the exceptions of nails, teeth and 
eyes. The skin organ is made up of layers, and thickness varies from 1.5-
4 mm. The most superficial layer, named epidermis, is thick epithelium; 
dermis lies below the epidermis and is composed of fibrous connective 
tissue. Innermost lies subcutis or hypodermis which is a fatty layer of 
adipose tissue not truly a part of the skin but of significance to the cuta-
neous passage of an implant abutment. 
 In the epidermis there are mainly four celltypes; keratinocytes, mela-
nocytes, Merkel cells and Langerhans cells. As their name indicate 
keratinocytes produce keratin, a structural protein that will give the skin 
protective entities. Apart from the mechanical properties, keratinocytes 
produce antimicrobial substances and neutralising enzymes that will in-
capacitate harmful chemicals. Keratinocytes are continuously regenerated 
and migrate upwards from the basal membrane. They are connected by 
anchor proteins so called desmosomes. Skin surface consists merely of 
dead keratinocytes and is renewed within 4-6 weeks. Thickness of the 
epidermis is proportional to the exposure of friction.   
 Epidermis divides into five layers at the most. The layers have their 
different characteristics and cell composition. The deepest skin layer 
named basal membrane (stratum basale) is a single row of cells with mi-
totic nuclei continuously undergoing cell division. Every 4th-10th cell in 
the basal membrane is a melanocyte responsible of melanin production, 
which gives us our pigment. It is enclosed into small granules that are 
passed outwards to the keratinocytes. In between these keratinocytes 
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there are Merkel cells with associated sensory nerve endings that respond 
to touch.  
 Next layer, stratum spinosum, is characterised by few cell divisions 
and keratinocytes tightly joined together by desmosomes. Dispersed 
throughout the layer are Langerhans cells, stellar formed type of dendritic 
cells that are part of our immune system.  
 Stratum granulosum consists of layers of flattened keratinocytes. 
Lamellate granules containing a hydrophobic glycolipid are produced by 
the cells and deposited extracellularly adding a waterproof character to 
the layer. The cell walls in the stratum granulosum are thicker, and to-
gether with the richness of tonofilament it resists tears and shreds. 
 Second outmost is the stratum lucidum, a layer with a mixed character 
of the adjacent layers. 
 The surface layer, stratum corneum, will be of different thickness de-
pending on the individual and where the skin is on the body. There is no 
cell division and all keratinocytes are flat and dead. They are joined by 
the keratohyalin from granules produced in deeper layers, giving protec-
tion from physical damage together with hydrophobic glycolipid. This is 
our protective shield towards water loss and rinse.(37)  
1.3 Surgical procedure 
When discovered that osseointegrated implants could transmit sound 
waves and bear weight load, implementation of BAHA and transfemoral 
amputation (TFA) prostheses treatment started. The procedure is surgical 
and will disrupt the skin barrier with all above mentioned components 
and layers of skin down to the periosteum. 
 Throughout time, different methods for the BAHA surgical procedure 
have been used however all creating sharp wound edges adjacent to the 
implant abutment.(38, 39) Today, implant insertion with percutaneous pas-
sage is performed in a one-stage procedure. Earlier, the implant was left 
for osseointegration and at a second-stage procedure, the percutaneous 
abutment was connected.  
 A skin flap has traditionally been lifted behind the ear, punched and 
folded over the abutment. There have also been different traditions of 
how to raise the flap, by a semi-circular or linear incision. There are 
severeal methods to reduce the skin in thickness and to remove hair folli-
cles with or without a dermatome. (40, 41) Hence, there is no consensus 
internationally on gold standard procedure. The skin thinning method is 
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now more or less abandoned. Instead the complete skin and soft tissue is 
preserved, either using a linear incision or a simple skin punch down to 
bone where the implant with the attached abutment is screwed firmly in 
the bone.(42-46) 
Children are often treated at a young age and mostly through a two-
stage procedure. This is to avoid trauma in the early post implant stage.  
Loading can, according to a consensus report from 2005, be from 3 
weeks.(47) 
For TFA treatment, the implant will be inserted at stage 1 and remain 
unloaded. After approximately 6 months healing period stage 2 is per-
formed. Muscle flaps are adjusted and skin is trimmed with thinning, re-
moval of subcutaneous fat and hairfollicles. The abutment will be press-
fitted firmly onto the implant and load bearing is strictly regulated and 
increased over the first 2-12 weeks after stage 2.(14, 48) 
1.4 Surgical complications 
At all times post surgery, inflammation occurs with typical features of 
rubor (rush), tumor (swelling) calor (heat/flush), dolor (pain), functio lae-
sa (loss of function) and in addition hematoma. 
 Wound infections of varying degree can occur. Features of infection 
are typically more intense and can cause spontaneous implant loss or 
need for local and/or oral antibiotics. It can be necessary to remove an 
implant and abutment surrounded with persistent skin reaction.(17, 33)    
 Necrosis of skin is one of the most severe complications to BAHA 
surgery. It occurs, when thinning the skin, which disrupts the blood circu-
lation and diffusion from submerging dermal layer.(49-51)  
 Numbness and loss of sensation can also be a lasting complication for 
patients, caused by trauma of small nerves in the skin when thinning the 
flap. In literature there are cases of local pain syndrome most likely 
caused by failed nerve healing. (16, 52)  
Along with skin thinning, hair follicles are removed and alopecia in 
the region of the abutment is to some individuals unaesthetic.   
1.5 Skin complications 
Skin complications in BAHA and FTA treatment are common and re-
ported frequently. (53, 54) Retrospective studies have been made on com-
plications of BAHA and need for skin corrections.(15, 55) Skin 
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complications are referred to as overgrowth of skin, dermatitis or postop-
erative flap complications.  
 The etiology of skin reactions is not fully understood. In 1984, von 
Recum et al. addressed different modes of the skin/implant junction and 
mechanisms of epidermal healing.(56) von Recum et al. postulated a pro-
cess resulting in failure; implant loss, by epidermal encapsulation. This 
epidermal proliferation and migration seeking to heal the wound eventu-
ally undermined the percutaneous device, much like a foreign body reac-
tion. In theory, this might cause skin overgrowth or skin downgrowth 
along the abutment and thereby jeopardising the osseointegration. 
 Holgers et al. 1999, stated that microbiological conditions from human 
percutaneous titanium implants in the head and neck region promote hy-
drophilic cell surfaces, which in turn make the infections around titanium 
implant curable by local treatment.(57) In orthopaedics different antibacte-
rial coatings on fracture fixation pins have been tried showing lower rates 
of tract infection.(58) The findings that antibacterial agents limit skin reac-
tions suggest that bacteria have an effect on the percutaneous passage.(59-
62) However, it is not clear wheather the skin reaction is a result of bacte-
ria or if the skin reaction promotes bacterial colonisation secondarily. It 
has also been argued that the property between the skin and titanium is a 
factor contributing to skin reactions, since the abutment of titanium does 
not adhere to the dermis. Studies have shown a layer of epidermal tissue 
between the skin and metal.(63, 64) 
 Jansen et al. (1994), demonstrated that less motion of skin around the 
abutment enhances the soft tissue condition.(65) They suggest less compli-
cations, the thinner the skin, due to less mobility of the interface of the 
abutment. This is also considered for intraoral implants, where keratin-
ised mucosa adjacent to the abutment could favour the prognosis of im-
plant survival.(66) In 2008, Wolf et al. presented new data on a simplified 
BAHA surgical procedure but still with skin reduction.(67) Reports from 
2010 describe that skin complications can occure likewise with skin re-
duction using dermatom or scapel. Recent reports suggest that the linear 
incision without thinning the skin at all show even less complications, 
hence the minimal invasive surgical BAHA procedure is of large benefit 
for the patient outcome.(15, 24, 68, 69) 
  
Hobson et al. 2010, also reported for BAHA, that there is an increased 
risk of skin complications seen among patients with Downs syndrome.(70) 
However literature lacks more data on, if some patient groups are more 
susceptible for adverse skin reactions than others. It is not further studied 
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if these complications are concentrated to any certain group of patients, 
i.e. patients with congenital malformations or syndromes. Hobson et al. 
2010, also reported that overall complications (soft tissue overgrowth, 
skin infection, abutment and fixture dislodgement, trauma, skull paraes-
thesia, persistent pain at abutment site, failure to osseointegrate) were 
23.9 % and revision was performed in 12.1 % in their study. This corre-
lates to previous studies that report a range between 8-59 % with revision 
rates of 5-42 %.(15) 
 
 In short term skin complications mimic those of inflammation post 
surgery. Over time skin reactions have been divided into different grades 
1-4 according to KM Holgers index, where 1 is least and 4 most affected 
skin and even implant loosening.(71, 72) It is not however a fact that all 
skin reactions will lead to loosening of the implant.(55)  
 
 Skin overgrowth is a common complication.(73, 74) The extent of over-
growth and under which timespan it developes vary in studies, ranging 
from partial cover of abutment to full overlap and from post operative 
healing 3 months and up to 2 years. 
1.4.1 Treatment of skin complications 
Patients are always recommended daily hygienic care such as wash or 
rinse.(55, 60) Local treatment with topical anti-flogistics and antibiotics is 
always used immediately post operative to avoid local reactions but can 
also cure symtoms later on.(60) Another treatment option might also be 
corticosteroid injections.(73)  
 Sometimes non-surgical treatment is not enough. Overgrowth of skin 
could be caused by chronic inflammation. However, it could also occur if 
an abutment is out of use for a longer period. Hence patients are advised 
to use their sound processor as consistently as possible. Invasive treat-
ment such as reduction of skin overgrowth with trimming or switching to 
a longer abutment can then become necessary.(5, 46, 74-76)  
 Adverse sensory conditions concerning pain are rare but hard to treat 
successfully and can at times be very disturbing for the patient.(16) 
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1.5 Abutment Material 
Traditionally, titanium has been used for both implant and abutment. In 
odontology implant and abutment material surfaces are widely investi-
gated and explored.(77) For intraoral abutments the trend has changed 
from titanium to ceramics for their supposed biocompability.(78) Percuta-
neous abutments are far less common and hence there is a sparse number 
of studies on the material use. Nevertheless different porosity of titanium 
coatings has been studied.(35, 79, 80) Literature reports different results from 
these studies suggesting there might be alternatives to pure titanium to 
favour connection to skin.(81, 82) 
1.5.1 Hydroxyapatite  
Ca10(Po4)6(OH)2 calcium phosphate ceramic named hydroxyapatite is a 
naturally occurring inorganic compound found most commonly in corti-
cal bone.(83) In our bodies hydroxyapatite can ouccur as highly crystalline 
or amphourus as it is continuously turnovered by the calcium haemostsis. 
Synthetic hydroxyapatite resembles the natural bioceramic well but is not 
as easily resorbed.(84) 
 In 1987, Aoki et al. reported on hydroxyapatite sintered abutments in 
an animal model showing that the material was closely connected with 
the skin and that epidermal downgrowth of epidermis was limited to 
1mm. After 3-17 months a fibrous capsule was formed with carachter-
sitics of periosteal tissue.(85) Some years after this in 1994 Thomas et al. 
wrote a review “Hydroxyapatite coatings” with the focus on integration 
of hydroxyapatite in bone.(83) They stated that hydroxyapatite forms a 
direct bond to living bone in orthopaedic use.(86-89)  
Hydroxyapatite can be applied on a surface through plasma spray, a pro-
cess that includes high temperatures. The compound can therefore change 
chemically and structurally. However, by means of x-ray diffraction 
(XDR) and FTIR spectroscopy characheristics can be defined.(83, 90, 91) 
Ca/P molar ratio of 1.67 is aimed for to simulate the biological hydroxy-
apatite in living bone.(92) 
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2 Aims 
The general aim for my thesis was to study the percutaneous abutment 
and its interaction with soft tissues. Specific aims for this thesis were to; 
 
1) Investigate skin reactions, implant complications and other pot-
ential co-morbidities. 
 
 
2) Investigate long-term survival rate of BAHA implants. 
 
 
 3) Develop new surgical techniques to improve and facilitate the 
soft tissue outcome, explore an alternative material for the abut-
ment to create a tighter adherence between dermis and the abut-
ment surface.   
 
 
      4) Describe the characteristics of the interfacial soft tissue next to 
the abutment. 
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3 Material and Methods  
3.1 Animal model 
3.1.1 Animals 
Animal experiments in paper II and III were approved by the Regional 
Ehtical Committee for Laboratory Animals at Gothenburg University and 
carried out within the international guidelines for ethical use of animals. 
The black female sheep were selected to be suitable because of their skull 
size and anatomy. It was a noveau animal model and study II was an an-
imal model trial as well. For both study II and III femal black sheep of 
average 50 kg were used and spent 2 weeks prior to the surgery in the 
laboratory housing for acclimatisation.  
The sheep were kept 2-3 per stable with ad libitum access to hay, food 
and water.  
3.1.2 Surgery 
After acclimatisation, the sheep underwent surgery during general anae-
thestics i.v (PropoVet 0.2 ml/kg) after sedation i.m with Dexdormitor 
0.015 mg/kg (Orion Pharma, Sollentuna, Sweden). After induction ani-
mals were intubated and kept at a minimal alveolar concentration 1.5 of 
isoflurane (Isoba; Intervet, Sollentuna, Sweden). All vital parameters 
were kept stable. To reverse Dexdormitor animals were given Antisedan 
0.075mg/kg (Orion Pharma, Sollentuna, Sweden). To maintain analgesia 
after surgery Temgesic 0.02 mg/kg was given. Desinfection with iodine 
solution was carried out as well as trimming of hair. 5 ml of 0.5 % Mar-
cain (Astra Zeneca, Södertälje, Sweden) was locally administrated at 
each surgical site. A 4- to 6 cm incision was placed behind and above the 
orbital rim and just in front of the ear bilaterally, Fig3. Elevation of peri-
osteal flap and insertion of 4 mm implants 3 on each side (Cochlear Ba-
haTM, BI300) approximately 5-10 mm apart with a premounted 9mm 
abutment (Cochlear BahaTM, BA300) were performed at a torque of 25 
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Ncm. Stability of the implant was verified using Ostell ISQ instrument 
Smart Peg type 55 (Ostell, Gothenburg, Sweden). In study II, four differ-
ent abutment configurations were used. According to a predefined rota-
tion scheme each animal received 1 or 2 of each abutment types: 1) 
standard titanium abutment (Cochlear BahaTM, BA300 Abutment), 2) 
standard tintanium Baha abutment coated with hydroxyapatite, 3) con-
cave titanium abutment and 4) concave hydroxyapatite coated abutment. 
In study III type 1 and 4 were used. 
 
 
Figure 3 Implant localisation in sheep  
For both study II and III. All sheep had 6 implants installed after a randomized protocol.  
3.2 Human model 
3.2.1 Patients 
Patients with traumatic loss or due to illness and were planned for cranio-
facial implants at the Universidade Paulista (UNIP) were included in a 
pilot study after ethical approval by the University board, according to 
Brazilian legislation. Patient consent was obtained for the option of hav-
ing healing abutment with hydroxyapatite (HA) (Test Abutment) as well 
as abutments of titanium (Ti) (Control Abutment). Patients’ treatment 
plan was not altered by the study. So far only 4 patients are included in 
the pilot study. 
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3.2.2 Material 
At least one Ti and one HA abutment all shaped as cylinders were used in 
each patient. Test abutments were made of titan grade 4, 6 mm high with 
a diameter of 3.2 mm, produced by KTMAB, Fig 4. HA abutments were 
plasma sprayed with 55-60 um-thick, 63 christallinity and Ca/p molar 
ratio of 1.67 HA by Cambioceramics (Zernikedreef Leiden Netherlands), 
similar to commercially used HA abutments, CochlearTM Baha® 
DermaLockTM Abutment (BA400). As HA will change charateristics 
when heated, Co-60 Gamma irraditation was used to obtain sterility 
(BBF Sterilisationssservice GmbH Kernen Germany. 
 
 
Figure 4 Healing abutment design  
Design of the healing test/control abutment prototype used in study IV.  
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3.2.3 Surgery 
During local anaesthesia (LA), insertion was performed according  to 
protocol. Each patient received at minimum one test and control abut-
ment, placed according to their therapeutic need, Fig5.  
 Surgical sites were irrigated with saline solution and the skin edges 
repositioned. No soft tissue reduction was performed. To ensure good 
adaptation between abutment and surrounding skin, a biopsy punch was 
used in 2 cases to adjust skin edges before suturing the soft tissue around 
abutments with none-resorbable sutures (Ethilon 4/0, Ethicon 
Johnsson&Johnsson). In one case implants were positioned outside the 
insicion line and the abutments had to be tunnelled through punched 
holes in the skin. Wounds were dressed with gauze and Terracortil Poly-
myxin B, Pfizer®. 
 After surgery patients were discharged from the hospital with pre-
scribed per os analgesics (5-10 mg Morphine, Paracetamol 1 g x4) for 14 
days and antibiotics (Flucloxacillin 1 g x3) for 7days. Removal of sutures 
and undressing were performed by hospital staff after 2 weeks. 
 Time to second surgery was between 8-12 weeks depending on 
surgeons decision. Local anaesthesia was administered via injection of 5 
ml Marcaine 0.5 %, and a 4 mm ø punch biopsy was used to collect the 
sample consisting of the abutment and the adjacent tissue. Samples were 
immediately fixated in 4 % paraformaldehyde. From each patient one test 
HA abutment and one control titanium abutment were taken.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Implant localisation (auricular) 
On the left hand side a test abutment with hydroxyapatit coating (greyish) and to the right hand side 
control abutment of titanium.  
 30 A N N A  L A R S S O N  
 
3.3 Methods related to the specific papers included in this 
thesis 
Paper I  
Data registered retrospectively were; number of implants, sex, age, thera-
peutic diagnosis, side of implantation, length of implant, one or two stage 
surgery, date of failure at the loss of implant, cause of failure grouped 
into; loss due to trauma=1, infection or lack of osseointegration=2, no 
beneficial sound function=3, removal of abutment but implant still in pa-
tient=4, removal because associated pain=5.  
Patients who underwent a standard two-stage procedure had a semilunar 
incision and a 4 months healing period prior to a second procedure with 
abutment attachment and loading at time of soft tissue healing. Patients 
who underwent a single stage procedure were treated with semilunar or 
linear incision and received an abutment on day of surgery but waited 6-
12 weeks before loading. 
Paper II  
Thirty-six Baha implants and abutments were inserted in the skull of six 
skeletally mature female black sheep without performing soft tissue re-
duction. Four different abutments were used. Healing times of one, two 
and four weeks were used (two animals per time point). Samples were 
analyzed using descriptive histology and morphometric measurements 
Fig 6.  
 
Figure 6 Histomorphometric measurments 
Schematic illustration of pocket depth (PD), epidermal downgrowth (EDG) 
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Paper III  
Forty-eight implants and abutments were inserted in the skull of six skel-
etally mature female black sheep without performing soft tissue reduc-
tion. Two different types of abutments (test and control) were inserted in 
the skull parietal part of eight sheep. Test abutments had a hydroxyap-
atite-coated surface and a concave shape. Conventional titanium abut-
ments were used as controls. A follow-up time of 4 weeks was used. 
Histomorphometric analyses of test and control samples were analyzed, 
and morphometric results were compared.  
Paper IV  
4 patients have so far been included in the pilot study. Two different 
abutements were used. Average healing time of 12 weeks. Samples were 
analyzed using descriptive histology and morphometric measurements. 
 
 
3.4 Histology 
Paper II, III, IV  
Histomorphometric analysis was in studies II, III carried out via photo-
micrographs and analysed by Easy Image 3000 (Tekno Optik AB 
Gothenburg Sweden) software. In study IV NIS-Elements D 3.2 64-bit 
software (Nikon Metrology, SARL Lises France) was used. Light micro-
scope images were in all studies obtained with a Nikon DS-Ri1 camera 
(Tekno Optik AB and Nikon Instruments Inc Meville, U.S.A). 
3.5 Statistical Analyses  
Paper I  
For this retrospective study, descriptive data, frequencies tables were 
computed.  Then also a Kaplan-Meier analysis was used to estimate the 
long-term survival rate of the titanium implants. Survival rate was esti-
mated for the total cohort of installed implants, as well as for only the 
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first implant. Kaplan Meier analysis was performed by an independent 
bio-statistician. 
Paper II  
For this first animal study Wilcoxon’s signed ranked test for statistical 
analysis of differences in histomorphometric parameters between abut-
ment types was used. In the comparisons all test samples were included 
irrespective of healing time. A 5 % significance level was adopted. Sta-
tistical analyses were performed by an independent bio-statistician. 
Paper III  
This second experimental study included more animals than in paper II 
and we opted for a mixed model analysis with implant and animal as 
fixed effects. Hence, adjustment of within animal correlation was possi-
ble and used for comparisons between test and control abutments. A 
mean value of measurements performed at the left and right side of each 
abutment was used in the analysis; implant loss and nonvalid data due to 
artifacts were considered as missing data and were not imputed. To de-
termine a 5 % significance level we used a Two-sided significance test. 
Statistical analyses were performed by an independent bio-statistician. 
Paper IV  
For the human pilot study we decided for a qualitative histomorphometric 
analysis and only a descriptive statistical analysis of differences in histo-
morphometric parameters between abutment types. In the comparisons 
all test samples were included irrespective of sample quality.  
 
 
 
 
 
 
  
 
 
 
4  RESULTS 33	  
4 Results 
4.1 Paper I 
Baha is a successful treatment however a small group of individuals rep-
resent repetitive failures. At the ENT department Sahlgrenska University 
hospital patients have had great possibility of rehabilitation with osseoin-
tegrated implants to conduct sound since 1977, Fig 7. 
 In our material that spans over the longest time in the world at time of 
the publication, we found that a small group of individs had an increased 
risk of implant loss. Out of 571 patinets treated and 763 implants insert-
ed, failure was seen in 46 (8.2 %) patients and 109 (14 %) implants were 
lost. Only 21 (3 %) implants were lost due to loss of osseointegration. 
 As the implants were inserted over a long period of time, different 
surgical techniques were used. The different surgical technique parameter 
was not studied in this paper. Our study suggests that there may be pa-
tients that are more prone to lose implants and that 4 mm implants have a 
higher survival rate than 3 mm implants 74 % vs 56 %) at 10 yrs. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Number of Baha implants 1977-2011 at Sahlgrenska ENT Department 
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4.2 Paper II 
The results from this experimental study showed that surgery with thin-
ning of the skin not is necessary when using hydroxyapatite abutments.  
 Histomorphometric analysis of the samples showed that tissues around 
all abutments had limited or no sign of inflammation. The hydroxyapatite 
abutments also showed signs of adherence to dermis compared to the ti-
tanium abutments that developed an epidermal downgrowth. Hydroxyap-
atite creates adherence to dermis in sheep. The concave hydroxyapatite 
abutment showed a tendency to have less epidermal downgrowth (1.53 
mm vs 1.12 mm p = 0.063) and pocket formation compared standard 
abutment shape (1.26 mm vs 0.83 mm p = 0.031), Fig 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Histomorphometric measurements (all healing times) (mm). A) Standard titanium Baha® abut-
ment, B) Standard titanium Baha® abutment coated with hydroxyapatite, C) Concave titanium abutment, 
D) Concave titanium abutment coated with hydroxyapatite 
  
4.3 Paper III 
Histomorphometic analysis showed a statistically significant difference 
in mean pocket depth between the hydroxyapatite concave shaped abut-
ment and standard titanium abutment (0.4 vs 1.6 mm p = 0.0013). Epi-
dermal down growth was also measured with a difference of 0.6 vs 2.0 
mm (p = 0.0003).   
 
p=0.031'
 Pocket depth (mm) 
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4.4 Paper IV 
Samples from 4 patients show an interphase between HA and dermis. All 
abutments showed limited or no signs of inflammation. Two patients’ 
samples had major artefacts. A limitation in this study is the sample retri-
val procedure and embedding of the samples. The artefacts may affect the 
histomorphometic and qualitative analyses.  
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5 Discussion 
 A sucessful treatment with osseointegrated implants relies on a biolo-
gical tolerability.(10, 18, 19, 93) Loosening of implants can occur for nume-
rous reasons and skin reactions might not correlate to implant loss, 
however, it might cause great inconvenience for the patient. (4, 9, 55, 94) 
 The effects on the soft tissue may, or may not, correlate to ongoing 
bone pathology causing implant loss.(55) In light of the results from the 
first paper in this thesis, it seems like a small number of patients are 
prone to loose implants. A small group of 19 patients counted for 78 (55 
%) out of 141 (of total 763) of the lost implants, and only 49 (8.2 %) of 
the patients lost one or more implants. This observation is in accordance 
with studies on intra oral implants by J Derks et al. 2015, where 33 % of 
lost implants were counted for in a small group of 19 patients losing 2 or 
more implants.(95) 
 Individual factors associated with oral implant failure have been stu-
died and Alsaadi, et al. in 2007 reported that patients with Mb Crohn, 
diabetes type I and patients treated with HRT (homone replacement 
therapy) had more complications and failures. Smokers have a higher 
odds ratio of early implant loss than non-smokers.(95-97)  
 In the retrospective study (Paper I) data for the subcohort of implant 
losses showed that males lost more implants and that 3 mm implant failed 
more often than 4 mm implants. Gender was not assessed in the review 
by Esposito et al. 1998 for intraoral implants, only age and genetics. 
Gender related differences in bone biology between males and females 
mostly occur postmenopausal and are more related to the large bones 
such a wrist, femur and spine.  
 In trials with shorter intraoral implants Rossi et al. 2016, showed that 
6mm implants work well over time but are sometimes affected by margi-
nal bone loss in the form of micro fractures.(98) 
 Moreover, in a consensus report 2018 on dental implants, the only 
contraindication for implant rehabilitation was in patients with ongoing 
high dose antiresorptive treatment due to cancer disease. These patients 
are designated to a high failure risk.(99)  
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 Pattern and etiopathogenesis of implant loss are multifactorial, and 
even recently described as an immunological reaction to a foreign body. 
(10, 100)  
Reactions against foreign bodies are inevitable but seem to differ depen-
ding on material and site. Osseointegrated implants have been widely 
explored over time but it might be that the peri-implant condition not at 
all is a disease as previously stated.(101) 
 In 1994 K-M Holgers presented a dissertation on the soft tissue react-
ions around titanium implants penetrating the skin. It has laid the foun-
dation for scoring of skin reactions and tissue charateristics adjacent to 
titanium abutments. Holgers stated that titanium creates no delayed hy-
persensivity, nor does it create any epithelial attatchment and that the soft 
tissue is loosely adaptive to the abutment. The loose character of the peri-
abutment soft tissue has been historically considered to be a reason for 
complications. (56, 102) Therefore thinning of the skin in variours ways has 
been a standard method. For patients undergoing surgery for bone an-
chored hearing aids this procedure compromises the esthetics and can 
also cause numbness in the peri-abutment area. In 2014, Hultkrantz et al. 
presented a 5 year follow-up study with bone anchored hearing device 
implantation without tissue reduction showing that this technique had 
fewer clinical complications than flap and dermatome techniques.(46) In 
2016 Roplekar et al. performed similar surgery and noted less clinical 
complications using a linear incision with tissue preservation.(103) Anot-
her technique towards less invasive surgical techniqe was also used by 
Gordon et al. 2015.(39) They suggested to use a punsch biopsy of the skin 
showing even less complications than the linear inscision preserving the 
skin.(104) In our second and third paper we developed an animal model to 
explore the histology of the skin adjacent to percutaneous abutment using 
skin presveration linear incision. The histological results from this 
material agree with the former studies that a percutaneous passage of 
bone anchored hearing aid can be achieved without thinning the skin. 
 The animal model also showed that HA could be of advantage for per-
cutaneous abutments and this correlates to earlier animal models.(105) HA 
has widely been studied for its osteoconductive properties, however, less 
extensive for its dermal interactions. In a work by Aoki et al. 1987, HA 
showed limited tendency to capsule formation around percutaneous de-
vices.(85) Twenty years later, DeJong et al. tried hydrodyapa-
tite/chlorhexidine coating in external fixator pins and had less infections 
compared to stainless steel and titanuim.(106) Skin irritation or infection 
are parameters that often represents clinical status of an percutaneous 
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abutment. However, it is not certain that soft tissue reactions lead to im-
plant loss(55, 63, 71, 100, 107)  
 HA interaction with human skin has also recently been studied by van 
Hoof et al. and Kapsokalyvas et al.(108, 109) Both authors suggested that HA 
can interact with dermis in a way not seen with titanium. Kapsokalyvas 
group also presented histology results of the periabutment soft tissue with 
immuhistochemistry and characterisation of hemidesmosomes and der-
mal collagene. These findings are, however, based upon few cases.  
 Case studies are unreliable to draw general conclusions from but are 
however necessary to further develop the biomaterials.  
 The last paper is in manuscript as a case study and further studies will 
hopefully result in a larger set of data and improved knowledge of percu-
taneous HA abutments characteristics in human. The protocol to use a 
healing abutment can give an opportunity to study histology in an unbi-
ased cohort of patients, excluding patients that have a clinical indication 
for abutment change or removal for other reasons. This human model 
could, however, be criticised since the healing time will not extend 12 
weeks and one could argue that at least 12 months follow-up time would 
represent a final outcome. Consensus from 2005 on healing times for 
bone anchored hearing aid implants is 4-6 weeks and for other craniofa-
cial implants there is no standard but in several studies healing times of 
3-6 months are reported. (27, 47, 110) 
 Parameters and effects of HA plasma sprayed on titanium as in study 
4, only present the effects of a narrow range of crystallinity 63 % as well 
as thickness mean 75 um. Jeyapalina et al. 2012 showed that a pourous 
titanium surface with the Ra(surface roughness)=1.7 +- 0.1 ug also gives 
an improved subderamal barrier.(34) This analysis was not performed on 
HA abutments as the crystallinity is a quality standard for bioceramics. 
Therefore the comparability is limited along with the difference in lipo-
phility and hydrophility.  
 The chemical interactions of HA and skin are not studied in this thesis 
but for HA and osteogenesis, Nakazawa et al. 2017 presented a cellcul-
ture study.(111) They noted that HA when exposed to cellcultures changed 
from hydrophobic to a hydrophilic surface and that titanium HA coated 
surface increased the osteoblastic proliferation without losing other 
chemical features.  
 One might say that HA merely changes the interaction with skin but it 
could not be said that this will affect the longterm outcome for the pa-
tient. There are few studies on percutaneous abutments with HA but sev-
eral for HA on other medical devices such as dental implants and hip- 
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and knee prostheses. Biomaterials need to be thoroughly tested in animal 
models as well as clinical trials before used as standard in surgical proce-
dures.  
 
 Even though study I is based upon a large data set it still is a ret-
roscpective study with limitations. Sahlgrenska ENT clinic was from the 
beginning a referral center for all bone anchored hearing aid treatments 
and therefor the mean follow-up time drops in comparison to internation-
al studies form Nijmegen 2008, 2013, Manchester 2009 and Birmingham 
1996, 2002. Hence the statistical method (Kapland- Meier analysis) had 
to avoid excluding patiens with short follow-up time. This statistical 
method will only give an estimate (Life table) on the survival rate of an 
implant instead of the actual time of survival. 
 
 In study II and III sheep were used to test biocompability of HA as 
well as surgical protocol. Pendegrass et al. 2006 used deer in a study of 
the skin barrier around percutaneous abutments, however animals cannot 
fully reflect the situation in humans.(59) Animals might be less sensitive 
for percutaneous passage or surgical technique. It could also be that these 
animals have a higher immunological tolerability to foreign bodies by 
evolution than humans. Animal studies will always just be a way to out-
rule truly adverse reactions.  
 
 The histological preparations of samples in study II, III and IV are 
well documented and used as standard methods for studying osseointgra-
tion along implants. However, artifacts in the samples might occur. There 
can be an alternation in the peri-abutment tissue when samples are taken 
from the animals or patients. Disintegration of the soft tissue from the 
abutment can also occur during fixation as well as shrinkage during the 
dehydration and embedding. Hence, results from the histomorphomet-
rical analyses in study II and III might, have been affected. However, 
very few artefacts were recorded. Also, histological analyses of HA vs 
titanium abutments can never be blinded, due to the totally different sur-
face appearances in the microscope. 
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6 Conclusions 
1) BAHA is generally a successful treatment but a small group of individ-
uals represent repetitive failures. 
 
2) Life table analysis showed long-term survival rate of 74 % for 4 mm 
BAHA implants and 56 % for 3 mm BAHA implants. 
 
3) The surgical procedure with thinning the skin is not necessary using 
hydroxyapatite abutments. 
 
4) Hydroxyapatite create adherence to dermis.  
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7 Future Perspective 
It is so fruitful to encourage the crossfield research with medical and dental ex-
periences of biomaterials and their usage as seen in the study by Albrektsson et 
al 2019 on foreign body reactions on dental implants and hip prostheses. In the 
field of biomaterial the collaboration of scientists with different focus is com-
mon.  
 For the future clinicians could also benefit from looking sideways, even 
though the biomaterial might be used in a different part of the body. A lot of the 
biological interactions can be similar and maybe even more similar than animal 
testing. It can hopefully be possible to do more testing on a cellular level with 
different biotech models/chambers resembling the human in an adequate way.  
Making animal and human trials unnecessary. 
 The future for BAHA has already proceeded a lot since these studies were 
performed and for patients with a need of BC hearing aid there are transcutane-
ous solutions today, without need for skin penetration. 
 HA remains an interesting biomaterial that is widely used for different appli-
cations today in medicin and hopes are that the development of HA applications 
can come to further progress in soft tissue interaction. 
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